The regulation of NK cell function and development

Frontiers in Bioscience

Volumn 13, Issue 17, 2008, Pages 6432-6442

  Chung, Jin Woong ^a   Yoon, Suk Ran ^a   Choi, Inpyo ^a  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Hematopoietic stem cells; Natural killer development; NK cell activity; NK cell therapy; Review

Indexed keywords

IMMUNOGLOBULIN RECEPTOR; TRANSCRIPTION FACTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; BONE MARROW CELL; CELL DIFFERENTIATION; CYTOLOGY; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPH NODE; LYMPHOCYTE TRANSFUSION; METABOLISM; METHODOLOGY; MOUSE; NATURAL KILLER CELL; NEOPLASM; PHYSIOLOGY; REVIEW; SPLEEN; THYMUS;

ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; HEMATOPOIETIC STEM CELLS; HOMEOSTASIS; HUMANS; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPH NODES; LYMPHOCYTE TRANSFUSION; MICE; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; SPLEEN; THYMUS GLAND; TRANSCRIPTION FACTORS;

EID: 52049083404     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: None     Document Type: Article

References (102)

1. Freud, A. G. & M. A. Caligiuri: Human natural killer cell development. Immunol Rev, 214, 56-72 (2006) (Pubitemid 44707902)
2. Petersson, M. G., A. Gronberg, R. Kiessling & M. T. Ferm: Engagement of MHC class I proteins on natural killer cells inhibits their killing capacity. Scand J Immunol, 42, 34-8 (1995)
3. Ljunggren, H. G. & K. Karre: Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med, 162, 1745-59 (1985) (Pubitemid 16149673)
4. Ljunggren, H. G., C. Ohlen, P. Hoglund, T. Yamasaki, G. Klein & K. Karre: Afferent and efferent cellular interactions in natural resistance directed against MHC class I deficient tumor grafts. J Immunol, 140, 671-8 (1988)
5. Saito, S., K. Nishikawa, T. Morii, M. Enomoto, N. Narita, K. Motoyoshi & M. Ichijo: Cytokine production by CD16-CD56bright natural killer cells in the human early pregnancy decidua. Int Immunol, 5, 559-63 (1993) (Pubitemid 23162525)
6. Maki, G., H. G. Klingemann, J. A. Martinson & Y. K. Tam: Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res, 10, 369-83 (2001) (Pubitemid 32673241)
7. Rosmaraki, E. E., I. Douagi, C. Roth, F. Colucci, A. Cumano & J. P. Di Santo: Identification of committed NK cell progenitors in adult murine bone marrow. Eur J Immunol, 31, 1900-9 (2001) (Pubitemid 32547352)
8. Ikawa, T., S. Fujimoto, H. Kawamoto, Y. Katsura & Y. Yokota: Commitment to natural killer cells requires the helix-loop-helix inhibitor Id2. Proc Natl Acad Sci U S A, 98, 5164-9 (2001) (Pubitemid 32397100)
9. Williams, N. S., J. Klem, I. J. Puzanov, P. V. Sivakumar, M. Bennett & V. Kumar: Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells. J Immunol, 163, 2648-56 (1999) (Pubitemid 29399189)
10. van den Brink, M. R., S. S. Boggs, R. B. Herberman & J. C. Hiserodt: The generation of natural killer (NK) cells from NK precursor cells in rat long-term bone marrow cultures. J Exp Med, 172, 303-13 (1990) (Pubitemid 20217272)
11. Ogasawara, K., S. Hida, N. Azimi, Y. Tagaya, T. Sato, T. Yokochi-Fukuda, T. A. Waldmann, T. Taniguchi & S. Taki: Requirement for IRF-1 in the microenvironment supporting development of natural killer cells. Nature, 391, 700-3 (1998) (Pubitemid 28113217)
12. Mrozek, E., P. Anderson & M. A. Caligiuri: Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells. Blood, 87, 2632-40 (1996) (Pubitemid 26102211)
13. Lee, K. N., H. S. Kang, J. H. Jeon, E. M. Kim, S. R. Yoon, H. Song, C. Y. Lyu, Z. H. Piao, S. U. Kim, Y. H. Han, S. S. Song, Y. H. Lee, K. S. Song, Y. M. Kim, D. Y. Yu & I. Choi: VDUP1 is required for the development of natural killer cells. Immunity, 22, 195-208 (2005) (Pubitemid 40255711)
14. Nakamura, K. & K. Matsunaga: Susceptibility of natural killer (NK) cells to reactive oxygen species (ROS) and their restoration by the mimics of superoxide dismutase (SOD). Cancer Biother Radiopharm, 13, 275-90 (1998) (Pubitemid 28484007)
15. Iizuka, K., D. D. Chaplin, Y. Wang, Q. Wu, L. E. Pegg, W. M. Yokoyama & Y. X. Fu: Requirement for membrane lymphotoxin in natural killer cell development. Proc Natl Acad Sci U S A, 96, 6336-40 (1999) (Pubitemid 29256666)
16. Lian, R. H., R. K. Chin, H. E. Nemeth, S. L. Libby, Y. X. Fu & V. Kumar: A role for lymphotoxin in the acquisition of Ly49 receptors during NK cell development. Eur J Immunol, 34, 2699-707 (2004) (Pubitemid 39430147)
17. Kather, A., S. Chantakru, H. He, K. Minhas, R. Foster, U. R. Markert, K. Pfeffer & B. A. Croy: Neither lymphotoxin alpha nor lymphotoxin beta receptor expression is required for biogenesis of lymphoid aggregates or differentiation of natural killer cells in the pregnant mouse uterus. Immunology, 108, 338-45 (2003) (Pubitemid 36332392)
18. Stevenaert, F., K. Van Beneden, V. De Colvenaer, A. S. Franki, V. Debacker, T. Boterberg, D. Deforce, K. Pfeffer, J. Plum, D. Elewaut & G. Leclercq: Ly49 and CD94/NKG2 receptor acquisition by NK cells does not require lymphotoxinbeta receptor expression. Blood, 106, 956-62 (2005) (Pubitemid 41076440)
19. Wu, Q., Y. Sun, J. Wang, X. Lin, Y. Wang, L. E. Pegg, A. Futterer, K. Pfeffer & Y. X. Fu: Signal via lymphotoxin-beta R on bone marrow stromal cells is required for an early checkpoint of NK cell development. J Immunol, 166, 1684-9 (2001) (Pubitemid 32114650)
20. Carson, W. E., J. G. Giri, M. J. Lindemann, M. L. Linett, M. Ahdieh, R. Paxton, D. Anderson, J. Eisenmann, K. Grabstein & M. A. Caligiuri: Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med, 180, 1395-403 (1994) (Pubitemid 24289613)
21. Budagian, V., E. Bulanova, R. Paus & S. Bulfone-Paus: IL-15/IL-15 receptor biology: a guided tour through an expanding universe. Cytokine Growth Factor Rev, 17, 259-80 (2006) (Pubitemid 44038618)
22. Vosshenrich, C. A., T. Ranson, S. I. Samson, E. Corcuff, F. Colucci, E. E. Rosmaraki & J. P. Di Santo: Roles for common cytokine receptor gamma-haindependent cytokines in the generation, differentiation, and maturation of NK cell precursors and peripheral NK cells in vivo. J Immunol, 174, 1213-21 (2005)
23. Ferlazzo, G., D. Thomas, S. L. Lin, K. Goodman, B. Morandi, W. A. Muller, A. Moretta & C. Munz: The abundant NK cells in human secondary lymphoid tissues require activation to express killer cell Ig-like receptors and become cytolytic. J Immunol, 172, 1455-62 (2004) (Pubitemid 38116788)
24. Klebb, G., I. B. Autenrieth, H. Haber, E. Gillert, B. Sadlack, K. A. Smith & I. Horak: Interleukin-2 is indispensable for development of immunological selftolerance. Clin Immunol Immunopathol, 81, 282-6 (1996) (Pubitemid 26414557)
25. Warren, L. A. & E. V. Rothenberg: Regulatory coding of lymphoid lineage choice by hematopoietic transcription factors. Curr Opin Immunol, 15, 166-75 (2003) (Pubitemid 36287522)
26. Singh, H., K. L. Medina & J. M. Pongubala: Contingent gene regulatory networks and B cell fate specification. Proc Natl Acad Sci U S A, 102, 4949-53 (2005)
27. DeKoter, R. P., H. J. Lee & H. Singh: PU.1 regulates expression of the interleukin-7 receptor in lymphoid progenitors. Immunity, 16, 297-309 (2002) (Pubitemid 34211968)
28. Colucci, F., S. I. Samson, R. P. DeKoter, O. Lantz, H. Singh & J. P. Di Santo: Differential requirement for the transcription factor PU.1 in the generation of natural killer cells versus B and T cells. Blood, 97, 2625-32 (2001)
29. Boggs, S. S., M. Trevisan, K. Patrene & K. Geogopoulos: Lack of natural killer cell precursors in fetal liver of Ikaros knockout mutant mice. Nat Immun, 16, 137-45 (1998) (Pubitemid 29271724)
30. Kee, B. L. & C. Murre: Induction of early B cell factor (EBF) and multiple B lineage genes by the basic helixloop- helix transcription factor E12. J Exp Med, 188, 699-713 (1998) (Pubitemid 28387933)
31. Zhuang, Y., P. Soriano & H. Weintraub: The helixloop- helix gene E2A is required for B cell formation. Cell, 79, 875-84 (1994) (Pubitemid 24371977)
32. Spits, H., F. Couwenberg, A. Q. Bakker, K. Weijer & C. H. Uittenbogaart: Id2 and Id3 inhibit development of CD34 (+) stem cells into predendritic cell (pre-DC)2 but not into pre-DC1. Evidence for a lymphoid origin of pre- DC2. J Exp Med, 192, 1775-84 (2000)
33. Samson, S. I., O. Richard, M. Tavian, T. Ranson, C. A. Vosshenrich, F. Colucci, J. Buer, F. Grosveld, I. Godin & J. P. Di Santo: GATA-3 promotes maturation, IFN-gamma production, and liver-specific homing of NK cells. Immunity, 19, 701-11 (2003) (Pubitemid 37490795)
34. Lohoff, M., G. S. Duncan, D. Ferrick, H. W. Mittrucker, S. Bischof, S. Prechtl, M. Rollinghoff, E. Schmitt, A. Pahl & T. W. Mak: Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells. J Exp Med, 192, 325-36 (2000)
35. Lian, R. H. & V. Kumar: Murine natural killer cell progenitors and their requirements for development. Semin Immunol, 14, 453-60 (2002)
36. Townsend, M. J., A. S. Weinmann, J. L. Matsuda, R. Salomon, P. J. Farnham, C. A. Biron, L. Gapin & L. H. Glimcher: T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity, 20, 477-94 (2004) (Pubitemid 38482125)
37. Taki, S., S. Nakajima, E. Ichikawa, T. Saito & S. Hida: IFN regulatory factor-2 deficiency revealed a novel checkpoint critical for the generation of peripheral NK cells. J Immunol, 174, 6005-12 (2005) (Pubitemid 40663787)
38. Colonna, M.: Immunoglobulin superfamily inhibitory receptors: from natural killer cells to antigen-presenting cells. Res Immunol, 148, 169-71 (1997) (Pubitemid 27304413)
39. Vance, R. E., J. R. Kraft, J. D. Altman, P. E. Jensen & D. H. Raulet: Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1 (b). J Exp Med, 188, 1841-8 (1998) (Pubitemid 28536771)
40. Lanier, L. L., B. C. Corliss, J. Wu, C. Leong & J. H. Phillips: Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature, 391, 703-7 (1998) (Pubitemid 28113218)
41. Wagtmann, N., S. Rajagopalan, C. C. Winter, M. Peruzzi & E. O. Long: Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity, 3, 801-9 (1995) (Pubitemid 26092193)
42. Moretta, A., C. Bottino, S. Sivori, E. Marcenaro, R. Castriconi, M. Della Chiesa, S. Carlomagno, R. Augugliaro, M. Nanni, M. Vitale & R. Millo: Natural killer lymphocytes: "null cells" no more. Ital J Anat Embryol, 106, 335-42 (2001)
43. Farag, S. S., T. A. Fehniger, L. Ruggeri, A. Velardi & M. A. Caligiuri: Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood, 100, 1935-47 (2002) (Pubitemid 35001221)
44. Steinle, A., P. Li, D. L. Morris, V. Groh, L. L. Lanier, R. K. Strong & T. Spies: Interactions of human NKG2D with its ligands MICA, MICB, and homologs of the mouse RAE-1 protein family. Immunogenetics, 53, 279-87 (2001) (Pubitemid 32678762)
45. Cosman, D., J. Mullberg, C. L. Sutherland, W. Chin, R. Armitage, W. Fanslow, M. Kubin & N. J. Chalupny: ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity, 14, 123-33 (2001) (Pubitemid 32206515)
46. Ljunggren, H. G. & K. Karre: In search of the 'missing self': MHC molecules and NK cell recognition. Immunol Today, 11, 237-44 (1990) (Pubitemid 20198988)
47. Valiante, N. M., M. Uhrberg, H. G. Shilling, K. Lienert-Weidenbach, K. L. Arnett, A. D'Andrea, J. H. Phillips, L. L. Lanier & P. Parham: Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity, 7, 739-51 (1997) (Pubitemid 28064888)
48. Draghi, M., N. Yawata, M. Gleimer, M. Yawata, N. M. Valiante & P. Parham: Single-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I. Blood, 105, 2028-35 (2005) (Pubitemid 40731788)
49. Fernandez, N. C., E. Treiner, R. E. Vance, A. M. Jamieson, S. Lemieux & D. H. Raulet: A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood, 105, 4416-23 (2005) (Pubitemid 40720789)
50. Kim, S., J. Poursine-Laurent, S. M. Truscott, L. Lybarger, Y. J. Song, L. Yang, A. R. French, J. B. Sunwoo, S. Lemieux, T. H. Hansen & W. M. okoyama: Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature, 436, 709-13 (2005) (Pubitemid 41117274)
51. Vitale, M., J. Zimmer, R. Castriconi, D. Hanau, L. Donato, C. Bottino, L. Moretta, H. de la Salle & A. Moretta: Analysis of natural killer cells in TAP2-deficient patients: expression of functional triggering receptors and evidence for the existence of inhibitory receptor (s) that prevent lysis of normal autologous cells. Blood, 99, 1723-9 (2002) (Pubitemid 34533047)
52. Yokoyama, W. M. & S. Kim: Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev, 214, 143-54 (2006) (Pubitemid 44707908)
53. Uhrberg, M., P. Parham & P. Wernet: Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics, 54, 221-9 (2002) (Pubitemid 34824132)
54. Makrigiannis, A. P., A. T. Pau, P. L. Schwartzberg, D. W. McVicar, T. W. Beck & S. K. Anderson: A BAC contig map of the Ly49 gene cluster in 129 mice reveals extensive differences in gene content relative to C57BL/6 mice. Genomics, 79, 437-44 (2002) (Pubitemid 34211952)
55. Williams, N. S., T. A. Moore, J. D. Schatzle, I. J. Puzanov, P. V. Sivakumar, A. Zlotnik, M. Bennett & V. Kumar: Generation of lytic natural killer 1.1+, Ly-49- cells from multipotential murine bone marrow progenitors in a stroma-free culture: definition of cytokine requirements and developmental intermediates. J Exp Med, 186, 1609-14 (1997) (Pubitemid 27479822)
56. Williams, N. S., A. Kubota, M. Bennett, V. Kumar & F. Takei: Clonal analysis of NK cell development from bone marrow progenitors in vitro: orderly acquisition of receptor gene expression. Eur J Immunol, 30, 2074-82 (2000) (Pubitemid 30456204)
57. Roth, C., J. R. Carlyle, H. Takizawa & D. H. Raulet: Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity, 13, 143-53 (2000)
58. Held, W., J. D. Coudert & J. Zimmer: The NK cell receptor repertoire: formation, adaptation and exploitation. Curr Opin Immunol, 15, 233-7 (2003) (Pubitemid 36287531)
59. Raulet, D. H., R. E. Vance & C. W. McMahon: Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol, 19, 291-330 (2001) (Pubitemid 32368038)
60. Freud, A. G. & M. A. Caligiur: Human natural killer cell development. Immunological Reviews, 214, 56-72 (2006) (Pubitemid 44707902)
61. Yokoyama, W. M.: Natural killer cell receptors. Curr Opin Immunol, 7, 110-20 (1995)
62. Ryan, J. C. & W. E. Seaman: Divergent functions of lectin-like receptors on NK cells. Immunol Rev, 155, 79-89 (1997) (Pubitemid 27076060)
63. Raulet, D. H., W. Held, I. Correa, J. R. Dorfman, M. F. Wu & L. Corral: Specificity, tolerance and developmental regulation of natural killer cells defined by expression of class I-specific Ly49 receptors. Immunol Rev, 155, 41-52 (1997) (Pubitemid 27076057)
64. Dorfman, J. R. & D. H. Raulet: Acquisition of Ly49 receptor expression by developing natural killer cells. J Exp Med, 187, 609-18 (1998) (Pubitemid 28093363)
65. Moretta, L. & A. Moretta: Killer immunoglobulin-like receptors. Curr Opin Immunol, 16, 626-33 (2004) (Pubitemid 39165891)
66. Lanier, L. L.: Face off-the interplay between activating and inhibitory immune receptors. Curr Opin Immunol, 13, 326-31 (2001) (Pubitemid 32537704)
67. Uhrberg, M., N. M. Valiante, B. P. Shum, H. G. Shilling, K. Lienert-Weidenbach, B. Corliss, D. Tyan, L. L. Lanier & P. Parham: Human diversity in killer cell inhibitory receptor genes. Immunity, 7, 753-63 (1997) (Pubitemid 28064889)
68. Trowsdale, J., R. Barten, A. Haude, C. A. Stewart, S. Beck & M. J. Wilson: The genomic context of natural killer receptor extended gene families. Immunol Rev, 181, 20-38 (2001) (Pubitemid 32703393)
69. Ljunggren, H. G. & K. J. Malmberg: Prospects for the use of NK cells in immunotherapy of human cancer. Nat Rev Immunol, 7, 329-39 (2007)
70. Smyth, M. J., E. Cretney, M. H. Kershaw & Y. Hayakawa: Cytokines in cancer immunity and immunotherapy. Immunol Rev, 202, 275-93 (2004) (Pubitemid 39576919)
71. Becknell, B. & M. A. Caligiuri: Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol, 86, 209-39 (2005) (Pubitemid 40215694)
72. Farag, S. S. & M. A. Caligiuri: Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma. Adv Pharmacol, 51, 295-318 (2004) (Pubitemid 39753953)
73. Rosenberg, S. A.: Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer. Cancer J Sci Am, 6 Suppl 1, S2-7 (2000)
74. Weiss, J. M., J. J. Subleski, J. M. Wigginton & R. H. Wiltrout: Immunotherapy of cancer by IL-12-based cytokine combinations. Expert Opin Biol Ther, 7, 1705-21 (2007) (Pubitemid 350157496)
75. Hayashi, T., T. Hideshima, M. Akiyama, K. Podar, H. Yasui, N. Raje, S. Kumar, D. Chauhan, S. P. Treon, P. Richardson & K. C. Anderson: Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol, 128, 192-203 (2005)
76. Brandau, S., J. Riemensberger, M. Jacobsen, D. Kemp, W. Zhao, X. Zhao, D. Jocham, T. L. Ratliff & A. Bohle: NK cells are essential for effective BCG immunotherapy. Int J Cancer, 92, 697-702 (2001) (Pubitemid 32385713)
77. Link, B. K., Z. K. Ballas, D. Weisdorf, J. E. Wooldridge, A. D. Bossler, M. Shannon, W. L. Rasmussen, A. M. Krieg & G. J. Weiner: Oligodeoxynucleotide pG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma. J Immunother (1997), 29, 558-68 (2006)
78. Rosenberg, S. A., M. T. Lotze, L. M. Muul, S. Leitman, A. E. Chang, S. E. Ettinghausen, Y. L. Matory, J. M. Skibber, E. Shiloni, J. T. Vetto & et al.: Observations on the systemic administration of autologous ymphokineactivated killer cells and recombinant interleukin-2 topatients with metastatic cancer. N Engl J Med, 313, 1485-92 (1985) (Pubitemid 16212345)
79. Rosenberg, S.: Lymphokine-activated killer cells: a new approach to immunotherapy of cancer. J Natl Cancer Inst, 75, 595-603 (1985) (Pubitemid 16222388)
80. Rosenberg, S. A., M. T. Lotze, L. M. Muul, A. E. Chang, F. P. Avis, S. Leitman, W. M. Linehan, C. N. Robertson, R. E. Lee, J. T. Rubin & et al.: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med, 316, 889-97 (1987) (Pubitemid 17041979)
81. Miller, J. S., Y. Soignier, A. Panoskaltsis-Mortari, S. A. McNearney, G. H. Yun, S. K. Fautsch, D. McKenna, C. Le, T. E. Defor, L. J. Burns, P. J. Orchard, B. R. Blazar, J. E. Wagner, A. Slungaard, D. J. Weisdorf, I. J. Okazaki & P. B. McGlave: Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood, 105, 3051-7 (2005)
82. Tam, Y. K., J. A. Martinson, K. Doligosa & H. G. Klingemann: Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. Cytotherapy, 5, 259-72 (2003) (Pubitemid 37086771)
83. Klingemann, H. G.: Natural killer cell-based immunotherapeutic strategies. Cytotherapy, 7, 16-22 (2005)
84. Shlomchik, W. D., M. S. Couzens, C. B. Tang, J. McNiff, M. E. Robert, J. Liu, M. J. Shlomchik & S. G. Emerson: Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science, 285, 412-5 (1999) (Pubitemid 29343964)
85. Ruggeri, L., M. Capanni, E. Urbani, K. Perruccio, W. D. Shlomchik, A. Tosti, S. Posati, D. Rogaia, F. Frassoni, F. Aversa, M. F. Martelli & A. Velardi: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science, 295, 2097-100 (2002) (Pubitemid 34229476)
86. Ruggeri, L., A. Mancusi, K. Perruccio, E. Burchielli, M. F. Martelli & A. Velardi: Natural killer cell alloreactivity for leukemia therapy. J Immunother 1997), 28, 175-82 (2005)
87. Miller, J. S., S. Cooley, P. Parham, S. S. Farag, M. R. Verneris, K. L. McQueen, L. A. Guethlein, E. A. Trachtenberg, M. Haagenson, M. M. Horowitz, J. P. Klein & D. J. Weisdorf: Missing KIR-ligands is associated with less relapse and increased graft versus host disease (GVHD) following unrelated donor allogenic HCT. Blood (2007)
88. Giebel, S., F. Locatelli, T. Lamparelli, A. Velardi, S. Davies, G. Frumento, R. Maccario, F. Bonetti, J. Wojnar, M. Martinetti, F. Frassoni, G. Giorgiani, A. Bacigalupo & J. Holowiecki: Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood, 102, 814-9 (2003) (Pubitemid 36917769)
89. Ruggeri, L., A. Mancusi, M. Capanni, E. Urbani, A. Carotti, T. Aloisi, M. Stern, D. Pende, K. Perruccio, E. Burchielli, F. Topini, E. Bianchi, F. Aversa, M. F. Martelli & A. Velardi: Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood (2007)
90. Ruggeri, L., A. Mancusi, E. Burchielli, F. Aversa, M. F. Martelli & A. Velardi: Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation. Cytotherapy, 8, 554-8 (2006) (Pubitemid 44869855)
91. Soiffer, R. J., E. P. Alyea, E. Hochberg, C. Wu, C. Canning, B. Parikh, D. Zahrieh, I. Webb, J. Antin & J. Ritz: Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant, 8, 625-32 (2002) (Pubitemid 35446754)
92. Passweg, J. R., A. Tichelli, S. Meyer-Monard, D. Heim, M. Stern, T. Kuhne, G. Favre & A. Gratwohl: Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia, 18, 1835-8 (2004) (Pubitemid 39530014)
93. Sentman, C. L., M. A. Barber, A. Barber & T. Zhang: NK cell receptors as tools in cancer immunotherapy. Adv Cancer Res, 95, 249-92 (2006) (Pubitemid 44066528)
94. Long, E. O., D. F. Barber, D. N. Burshtyn, M. Faure, M. Peterson, S. Rajagopalan, V. Renard, M. Sandusky, C. C. Stebbins, N. Wagtmann & C. Watzl: Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol Rev, 181, 223-33 (2001) (Pubitemid 32703410)
95. Sutherland, C. L., B. Rabinovich, N. J. Chalupny, P. Brawand, R. Miller & D. Cosman: ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood, 108, 1313-9 (2006) (Pubitemid 44232030)
96. Skov, S., K. Rieneck, L. F. Bovin, K. Skak, S. Tomra, B. K. Michelsen & N. Odum: Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood, 101, 1430-8 (2003) (Pubitemid 36182517)
97. Olszewski, A. J. & M. L. Grossbard: Empowering targeted therapy: lessons from rituximab. Sci STKE, 2004, pe30 (2004)
98. Adams, G. P. & L. M. Weiner: Monoclonal antibody therapy of cancer. Nat Biotechnol, 23, 1147-57 (2005) (Pubitemid 41486396)
99. Marcus, R. & A. Hagenbeek: The therapeutic use of rituximab in non-Hodgkin's lymphoma. Eur J Haematol Suppl5-14 (2007) (Pubitemid 44934857)
100. Hartmann, F., C. Renner, W. Jung, L. da Costa, S. Tembrink, G. Held, A. Sek, J. Konig, S. Bauer, M. Kloft & M. Pfreundschuh: Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res, 7, 1873-81 (2001) (Pubitemid 32994820)
101. Suck, G.: Novel approaches using natural killer cells in cancer therapy. Semin Cancer Biol, 16, 412-8 (2006) (Pubitemid 44322046)
102. Krause, S. W., R. Gastpar, R. Andreesen, C. Gross, H. Ullrich, G. Thonigs, K. Pfister & G. Multhoff: Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase I trial. Clin Cancer Res, 10, 3699-707 (2004) (Pubitemid 38697603)